Genmab — April 2014
-
http://www.reuters.com/article/2014/04/26/us-merck-co-sale-idUSBREA3P0I220140426?feedType=RSS&feedName=innovationNews&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+news%2Fdeals+(Reuters+Deals+News) skal love for der er gang i de store handler. Vi mangler stadig,
-
Novod om dansk biotek http://www.proinvestor.com/investornyt/123647/nordea-ser-staerk-dansk-bioteksektor
-
stiger marginalt under meget svag volumen - er vi ved at se et paradigmeskifte i kursudviklingen? Dog er usual suspects (n/a og Deutsche) på salgssiden
-
så længe volumen ikke er højere, så er skaden ikke så stor
-
Der kommer arzerratal fra GSK på onsdag
-
Det er flot som GEN følger US op
-
well, den sluttede ikke i minus. Og det er jo altid en god ting...
-
jeg faldt over denne: Ofatumumab i ALL CVAD. All eighteen (100%) pts achieved minimal residual disease (MRD) negativity as assessed by FCI; (…) With a median follow up of 8 months (1-23), 18 pts are alive and in CR; (…) The 1-year CRD and overall survival rates were 100% and 95% respectively.
-
-
lyder interessant - men jeg ved ikke lige hvordan landet ligger med Novartis på ALL og CLL. De har CTL-19, der ser ganske potent ud - http://www.bloomberg.com/news/2013-12-18/novartis-needs-special-delivery-for-potent-cell-therapy.html
-
GSK har 2 abstracts med som poster og oral præsentation på American Academy of Neurology årsmøde i morgen. Begge fra MIRROR studiet.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind